ValoTx 04/08/2022

Valo Introduction Video

Valo Therapeutics (ValoTx) is a developer of novel immunotherapies in cancer and infectious disease.

Their unique approach to immunotherapy, based on oncolytic viruses and viral vectors combined with disease-specific peptides, delivers highly adaptable and immunogenic therapeutic vaccination platforms. A spin-out company from the University of Helsinki, Finland, Valo Tx has assembled a talented team of immunotherapy experts, who together with the founding scientists have the necessary expertise to take its patented technology through clinical development and make it available to patients. The management team has a proven track record of developing successful companies from a laboratory idea to a full stock exchange listing.

Back to News

Related Articles

ValoTx

Valo Therapeutics Oy Shareholder Update 

05/08/2022 Read more
ValoTx

Valo Immuno-Oncology Treatment

09/08/2022 Read more
ValoTx

Nordic Life Sciences Interview: Valo Therapeutics CEO Paul Higham

24/10/2022 Read more
ValoTx

Valo Therapeutics Announces First Patient Dosed with PeptiCRAd-1 – Innovative Immuno-oncology 

26/06/2023 Read more